D. Ilegbodu
About
D. Ilegbodu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, D. Ilegbodu has authored 30 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in D. Ilegbodu's work include Cancer Treatment and Pharmacology (16 papers), Lung Cancer Treatments and Mutations (12 papers) and Colorectal Cancer Treatments and Studies (8 papers). D. Ilegbodu is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Lung Cancer Treatments and Mutations (12 papers) and Colorectal Cancer Treatments and Studies (8 papers). D. Ilegbodu collaborates with scholars based in United States and Canada. D. Ilegbodu's co-authors include Lina Asmar, David Loesch, Robert N. Raju, Robert J. Belt, Kathy S. Albain, Melody Cobleigh, Brian Leyland‐Jones, Nicholas J. Robert, Lea Fuchs and Robert M. Sayre and has published in prestigious journals such as Journal of Clinical Oncology, Lung Cancer and Investigational New Drugs.
In The Last Decade
D. Ilegbodu
29 papers receiving 693 citations
Peers
D. Ilegbodu
Saverio Danese Italy
Alexandre Bodmer Switzerland
Massimo Rinaldo Italy
Reshma Mahtani United States
I. E. Smith United Kingdom
Gabriel Hortobagyi United States
T Yoshikubo Japan
Angela Sciandivasci Italy
Shoshu Mitsuyama Japan
Janice F. Eakle United States
Citations per year, relative to D. Ilegbodu D. Ilegbodu (= 1×)
peers
Saverio Danese
Countries citing papers authored by D. Ilegbodu
Since
Specialization
Citations
This map shows the geographic impact of D. Ilegbodu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Ilegbodu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Ilegbodu more than expected).
Fields of papers citing papers by D. Ilegbodu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by D. Ilegbodu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Ilegbodu. The network helps show where D. Ilegbodu may publish in the future.
Co-authorship network of co-authors of D. Ilegbodu
This figure shows the co-authorship network connecting the top 25 collaborators of D. Ilegbodu. A scholar is included among the top collaborators of D. Ilegbodu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Ilegbodu. D. Ilegbodu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Carter, Dennis L., David Garfield, James W. Hathorn, et al.. (2011). A Randomized Phase III Trial of Combined Paclitaxel, Carboplatin, and Radiation Therapy Followed by Weekly Paclitaxel or Observation for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(3). 205–213.
2.
Jones, Stephen E., Christopher Stokoe, Mark D. Sborov, et al.. (2008). The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer. Clinical Breast Cancer. 8(6). 527–532.
3.
Cohn, Allen Lee, et al.. (2008). A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Investigational New Drugs. 26(4). 381–386.
4.
Carter, Dennis L., Lina Asmar, Mark Allen O’Rourke, et al.. (2008). Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma. Investigational New Drugs. 26(5). 473–481.
5.
Hutson, Thomas E., Svetislava J. Vukelja, Daniel Atienza, et al.. (2008). Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Investigational New Drugs. 26(2). 151–158.
6.
Blum, Joanne L., Elizabeth Claire Dees, Svetislava J. Vukelja, et al.. (2007). Phase II Trial of Capecitabine and Weekly Paclitaxel in Patients with Metastatic Breast Cancer Previously Treated with Every-3-Week Taxane Therapy. Clinical Breast Cancer. 7(6). 465–470.
7.
Jones, Stephen E., James Cantrell, Svetislava J. Vukelja, et al.. (2007). Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy. Journal of Clinical Oncology. 25(30). 4765–4771.
8.
Robert, Nicholas J., Brian Leyland‐Jones, Lina Asmar, et al.. (2006). Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 24(18). 2786–2792.
9.
O’Shaughnessy, Joyce, et al.. (2006). Phase II Trial of Weekly Docetaxel/Gemcitabine as First-Line Chemotherapy in Patients with Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 6(6). 505–510.
10.
Berry, William R., et al.. (2006). A Phase II Study of Weekly Paclitaxel/Estramustine/Carboplatin in Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(2). 131–137.
11.
Kolodziej, Michael, Marcus A. Neubauer, Steven R. Rousey, et al.. (2006). Phase II Trial of Docetaxel/Capecitabine in Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(2). 155–161.
12.
Blum, Joanne L., Elizabeth Claire Dees, Judith O. Hopkins, et al.. (2006). Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 24(27). 4384–4390.
13.
Cartwright, Thomas H., Allen Lee Cohn, William Hyman, et al.. (2006). Results of a phase II trial of cetuximab+XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer. Journal of Clinical Oncology. 24(18_suppl). 13502–13502.
14.
Sandbach, John F., et al.. (2006). Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2. Lung Cancer. 52(3). 313–317.
15.
Cox, John V., Thomas H. Cartwright, M. Neubauer, et al.. (2006). A Phase II study of gemcitabine plus zoledronic acid in subjects with Stage IV pancreatic cancer. Journal of Clinical Oncology. 24(18_suppl). 14002–14002.
16.
Hutson, Thomas E., Svetislava J. Vukelja, Steven J. Nicol, et al.. (2006). Phase I study of gemcitabine and cisplatin followed by pemetrexed and gemcitabine in patients with metastatic transitional cell carcinoma of the urothelium: Preliminary results. Journal of Clinical Oncology. 24(18_suppl). 14550–14550.
17.
Loesch, David, et al.. (2006). Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu–Negative Metastatic Breast Cancer: A Community-Based Study. Journal of Oncology Practice. 2(6). 268–273.
18.
Berry, William R., et al.. (2006). Docetaxel in combination with radiation in prostate cancer: A phase I dose-finding study. Journal of Clinical Oncology. 24(18_suppl). 14649–14649.
19.
Robert, N. J., Brian Leyland‐Jones, Lina Asmar, et al.. (2004). Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Journal of Clinical Oncology. 22(14_suppl). 573–573.
20.
Sandbach, John F., et al.. (2004). A phase II study of weekly docetaxel and carboplatin in stage IIIB (with effusion) or stage IV non-small cell lung cancer patients age <65 and performance status 2. Journal of Clinical Oncology. 22(14_suppl). 7276–7276.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Saverio Danese Breakdown of academic impact, for papers by Alexandre Bodmer Breakdown of academic impact, for papers by Massimo Rinaldo Breakdown of academic impact, for papers by Reshma Mahtani Breakdown of academic impact, for papers by I. E. Smith Breakdown of academic impact, for papers by Gabriel Hortobagyi Breakdown of academic impact, for papers by T Yoshikubo Breakdown of academic impact, for papers by Angela Sciandivasci Breakdown of academic impact, for papers by Shoshu Mitsuyama Breakdown of academic impact, for papers by Janice F. Eakle